Answers are grounded in this paper and cite their sources.
Randomised trial shows no significant benefit of secukinumab over placebo in lupus nephritis patients, indicating limited efficacy.
Objectives To evaluate the efficacy and safety of subcutaneous secukinumab 300 mg combined with standard of care (SoC) in adult patients with active lupus nephritis (LN). Methods The core study was a phase-III, randomised, placebo-controlled, double-blind study (planned duration: 104 weeks) of patients with active LN. Eligible patients were randomised to receive secukinumab 300 mg or placebo for the first 4 weeks followed by a monthly maintenance dose, with all patients receiving a SoC background regimen. Patients completing the 104-week treatment of the core study were eligible for an open-label extension study (planned duration: up to 260 weeks) to receive secukinumab 300 mg every 4 weeks. Primary end point of the core study was the proportion of patients achieving complete renal response (CRR) at week 52. Results Both studies were terminated early following a planned futility analysis in the core study showing no clinically meaningful benefit of secukinumab over placebo. In the core study, the proportion of patients achieving CRR at week 52 was lower with secukinumab (24.2%) than with placebo (36.3%). No differences were observed between the secukinumab and placebo groups in any of the secondary endpoints of the core study. The incidence of treatment-emergent adverse events was comparable between the secukinumab and placebo groups. In the extension study, results were not interpretable owing to the low patient number included in the data analysis (n = 31). Conclusion Secukinumab did not demonstrate superior efficacy over placebo in patients with active LN. Secukinumab was well-tolerated with no new or unexpected safety signals detected. Trial registration NCT04181762 (Novartis study code: CAIN457Q12301). NCT05232864 (Novartis study code: CAIN457Q12301E1)
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: